MARKET

NURPF

NURPF

Neuren Pharma
OTCPK
9.25
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
9.25
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
15.15
52 WEEK LOW
7.83
MARKET CAP
1.17B
P/E (TTM)
59.56
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Neuren Pharmaceuticals Limited (NURPF), Design Therapeutics (DSGN)
TipRanks · 1d ago
Neuren launches Investor Hub to bolster engagement as neurological pipeline advances
TipRanks · 05/12 06:05
Neuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity
TipRanks · 05/11 23:24
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF), Astrana Health (ASTH) and Pacific Biosciences (PACB)
TipRanks · 05/11 01:20
Analysts Offer Insights on Healthcare Companies: Imugene (OtherIUGNF) and Neuren Pharmaceuticals Limited (OtherNURPF)
TipRanks · 05/09 09:05
Bell Potter Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 05/09 09:05
Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting
TipRanks · 04/24 03:38
Neuren Sets Hybrid 2026 AGM, Puts Director Re-election to Shareholder Vote
TipRanks · 04/24 03:37
More
About NURPF
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Webull offers Neuren Pharmaceuticals Ltd stock information, including OTCPK: NURPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NURPF stock methods without spending real money on the virtual paper trading platform.